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Objective: There is a need to ﬁnd biochemical markers that would identify people with increased risk of
developing radiographic knee osteoarthritis (RKOA). The aim of this study was to evaluate the ability of
cartilage and bone biomarkers (cartilage oligomeric matrix protein (COMP), aggrecan, cellular inhibitor
of apoptosis protein (cIAP), N-telopeptide-to-helix (NTx)) to predict RKOA incidence in a 10-year follow-
up of UK females from the Chingford community study.
Method: Joint space narrowing (JSN), osteophytes (OSP) and KellgreneLawrence (K/L) grades were scored
from radiographs of both knees at study baseline and 10 years later in 1,003 women aged 45e64.
Circulating levels of biomarkers and demographic variables were measured at baseline. Statistical as-
sociation analysis was conducted between the potential predictor factors measured at baseline and
documentation of RKOA at 10-year follow-up.
Results: Age and body mass index (BMI), were signiﬁcant predictors of incidence of RKOA as assessed by
K/L and OSP. Considering biomarkers, independent signiﬁcant association was found between COMP
circulating levels and K/L scores (Odd Ratio (OR) ¼ 2.87, 95% Conﬁdence Interval (CI) ¼ 1.19e6.89,
P ¼ 0.018). Signiﬁcant negative association was detected between aggrecan plasma concentrations and
JSN, with OR ¼ 0.37 (95% CI 0.15e0.89), P ¼ 0.026.
Conclusions: Aggrecan and COMP circulating levels contribute to identiﬁcation of phenotype-speciﬁc
RKOA incidence. These data suggest potentially protective role of aggrecan in cartilage loss, as
measured by JSN. High COMP levels are risk factors for development of RKOA, as assessed by K/L scores.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Knee osteoarthritis (KOA) is a highly prevalent age-related
degenerative disease of synovial joint1. The knee joint is a com-
plex organ, and the main pathologic changes seen in KOA include
inﬂammation of the joint lining synovial membrane (synovitis),
ﬁbrillation and loss of the articular cartilage, accompanied by
thickening and remodeling of the subchondral bone. Ultimately, it
results in full thickness loss of cartilagewhich is seen on radiograph
as loss of joint space2,3. The involvement of a variety of tissues re-
sults in the appearance and interactions of many types of mole-
cules, both locally and in circulation4e6. The identiﬁcation of blood: G. Livshits, Department of
cine, Tel Aviv University, Tel
8287.
s Research Society International. Pand urine biomarkers or combination of biomarkers that might
be useful and reliable indicators of the disease incidence and pro-
gression remains an important challenge6e8. Until now there is no
wide agreement on best and most effective circulating bio-
markers9,10 but there are number of molecules, whose circulating
levels appear to be associated with OA. Among these molecules, are
those related to cartilage metabolism, namely, aggrecan, cartilage
oligomeric matrix protein (COMP), cellular inhibitor of apoptosis
protein (cIAP) and molecule related to bone metabolism, N-telo-
peptide-to-helix (NTx), secreted following bone resorption. The
association of the circulating levels of the aforementioned mole-
cules with manifestation and rate of progression of joint destruc-
tion in patients with KOA have been tested in several studies11e18,
with conﬂicting results. For example, there are a series of studies
reporting more rapid knee joint destruction in patients with lower
levels of aggrecan in synovial ﬂuid and/or in serum in comparison
to patients with higher levels19,20. Other studies, however, found anublished by Elsevier Ltd. All rights reserved.
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potential marker of OA progression is a non-collagenous protein of
articular cartilage matrix COMP, which may protect chondrocytes
cells against death24. Several studies demonstrated consistently
elevated COMP levels in synovial ﬂuid and/or serum during periods
of arthritic changes in knee joint15,21,25. Yet, other studies found no
such correlation26,27. There are also data concerning the NTx and
cIAP association with OA are controversial and inconsistent26,28e32.
Thus, there is uncertainty with respect of usefulness of the afore-
mentioned markers of osteoarthritis in general and for KOA, in
particular. One potential reason for such uncertainty could be the
limited statistical power of many of these studies due to their
relatively small sample size, ranging between a few dozens to a
couple of hundreds individuals.
We have collected radiographic knee osteoarthritis (RKOA) data
over 10-years in a large community-based sample of middle-aged
British females. The goal of this study was to investigate whether
circulating levels of COMP, aggrecan, NTx and cIAP predict
appearance of RKOA-associated phenotypes followed prospectively
during 10 years.
Material and methods
Study subjects
A detailed description of the sample, its recruitment, radio-
graphic and clinical assessment has been published previously
elsewhere33. Brieﬂy, the Chingford Study population was estab-
lished in 1989 as a caseecontrol study to determine prevalence
rates of OA in middle-aged women in the general population, but
since become a prospective population-based longitudinal cohort
of women seen annually and described in detail by Spector et al.34.
The original response rate of the sample was 78%. The cohort
consisted initially of 1,003 middle-aged women aged 45e64 from
a general practice in Chingford, northeast London. All participants
gave written informed consent before entering the study and the
St. Thomas’ Hospital research ethics committee approved the
project.
Radiographic assessment
Plain AP radiographs were scored by single trained reader who
was blinded to the pairing or clinical information. The status of each
RKOA was determined based on two characteristics, and following
Altman atlas35: 1. The Kellgren/Lawrence (K/L) scores ranging from
0 (no evidence of bony changes or joint space narrowing (JSN)) to 4
(deﬁnite osteophytes (OSP) and increasing diminution of the joint
space). 2. JSN and OSP score, graded on four-point scale (where
0 ¼ OSP (or JSN) are not observable, and 3 ¼ most severe status).
The assessment of JSN and OSP was done for lateral and medial
compartments on each knee separately. An individual was
considered ”affected“ if at least one knee had K/L 2, or if OSP and/
or JSN 1. RKOA was assessed twice, ﬁrst at entrance examination
and then 10 years later on ﬁlms which were not paired.
Biomarkers measurements
Blood and urine samples were obtained at baseline examination
and methodology was described in details elsewhere30. In short,
sera were stored at 80C after being obtained from venous blood.
The circulating levels of all biomarkers were assayed using Enzyme
Linked Immunosorbent Assay (ELISA) kits and following manu-
facturer instructions. Urine NTx levels were measured using an
Osteomark NTx kit (Inverness Medial Innovations, Princeton NJ,
USA) and themeasured values were corrected renal function. Bloodserum samples were used to assay circulating levels of aggrecan,
COMP, and cIAP, using kits manufactured by Medgenix Diagnostics
(Belgium), AnaMar Medical (Uppsala, Sweden), and Bio-Rad pro-
tein Assay kit (Hercules, CA), respectively.
Statistical analysis
This was performed using SPSS package version 19 (SPSS Inc,
Chicago, IL, USA), to identify variables, which potentially could be
able to predict incidence of primary RKOA, 10 years after the bio-
markers assessment. All individuals with K/L grading >1 and/or
OSP and/or JSN grading >0 at baseline, and those who underwent
total knee replacement during the 10-year follow-up, were
excluded from the analysis (N ¼ 136 individuals). We then con-
ducted a series of univariate analyses to determine the relationship
of RKOA with body mass index (BMI), and circulating levels of
biomarkers, without adjusting for age. RKOA phenotypes, in these
analyses, were treated as categorical variables in which individuals
not affected at either entrance examination or 10-year follow-up
(control) were contrasted with the individuals not affected at
baseline, but affected after 10 years (case). Since distributions of the
biochemical variables exhibited statistically signiﬁcant skewness
(P  0.01), we implemented non-parametric ManneWhitney tests
to compare cases and controls. Next, we conducted a binary logistic
regression analysis in which dependent RKOA variables were
treated as categorical traits: case vs control. Age, BMI and bio-
markers were used as independent predictors in this analysis and
as confounders for adjustment.
Results
The basic characteristics of the study sample used in prediction
analysis are given in Table I. At baseline examination, 1,003 par-
ticipants were recruited. Of these, 909 had complete radiographic
data, of which 865 had complete blood and urine biomarkers data.
For prediction analysis the following sample sizes were ob-
tained:742,784,780,694,788 participants for K/L, OSP_md, OSP_lt,
JSN_md, JSN_lt, respectively. These individuals were unaffected at
baseline, and had full data at baseline and 10 years after (Appendix
1). Individuals who were not included in the analysis tended to be
older (57  0.40 vs 54  0.21) and heavier (BMI 27  0.33 vs
25  0.14) than those included in the study. Univariate analyses
showed the controls were signiﬁcantly (P  0.002) younger than
cases deﬁned by K/L and OSP, but not JSN. BMI and COMP tended to
be signiﬁcantly higher in the cases for all phenotypes, except
JSN_md. Mean aggrecan serum concentrations were consistently
lower in the cases, but the difference was not signiﬁcant for JSN_lt.
cIAP and NTx levels showed no clear trend in relation to any of the
RKOA phenotypes. Table II summarizes the main results of binary
logistic regression. As expected, age and BMI were signiﬁcant
predictors for K/L and OSP at both compartments. In addition, BMI
was signiﬁcantly associated with JSN_lt. Considering biochemical
factors; COMP was a signiﬁcant predictor for K/L only. Its inde-
pendent effect was quite substantial, as measured by relative risk,
RR ¼ 2.87 (95% Conﬁdence Interval (CI) 1.19e6.89), P ¼ 0.018. Fig. 1
shows that risk probability of developing RKOA (K/L  2) increases
with the elevation of age, BMI and COMP concentration. The
aggrecan circulating levels were statistically signiﬁcantly lower in
affected participants with the OA phenotype as assessed by
JSN_md 1 (P¼ 0.026) and its elevated levels were associated with
reduced relative risk, RR ¼ 0.37 (95% CI 0.15e0.89), Table II. These
data thus suggest that aggrecan levels in some way act as a pro-
tective factor against cartilage destruction and narrowing of joint
space. The two other biomarkers cIAP and NTx were not associated
signiﬁcantly with any of the RKOA phenotypes.
Table I
Basic descriptive statistics of Chingford sample used to examine the risk factors for OA-related phenotypes incidence during 10 years of follow-up. The sample divided into
cohorts: (a) Individuals with “not affected” radiographic imaging at baseline and after 10 years (control), and (b) individuals with “not affected” radiographic imaging at
baseline and "affected" after 10 years (case). ManeWhitney test was used to compare distribution of quantitative covariates between the case and control cohorts. OSP_lt and
OSP_md eOSP from lateral and medial compartments of tibiofemoral joint, JSN_ lat and JSN_md e are JSN of lateral and medial compartments at visit_10 (10 years after
baseline)
Predictors Individuals with “not affected” radiographic
imaging at baseline and after 10 years.
Control.
Individuals with "not affected" radiographic
imaging at baseline and "affected" after
10 years. Case.
ManeWhitney test Incidence/1,000
N Mean (SD) Range N Mean (SD) Range P-value
K/L scores
Age_ (years) 565 53.5 (5.8) 44.6e66.0 208 55.5 (5.8) 45.1e66.7 0.001 269
BMI (kg/m2) 565 24.7 (3.7) 18.8e47.3 208 26.4 (4.4) 18.4e44.5 0.001 269
COMP (mg/ml) 539 1583.8 (330.6) 745e3,101 203 1680.5 (364.2) 943e3,436 0.001 273.6
Aggrecan (mg/ml) 539 2947.6 (789.1) 1,235e6,230 203 2823.0 (774.5) 1,471e6,160 0.014 273.6
cIAP (ng/mmol) 539 1637.7 (1012.1) 100e6,846 203 1750.6 (1059.6) 100e6,507 0.204 273.6
NTx (nmol/mmol) 538 16.9 (4.7) 8e58.4 203 17.5 (5.6) 7.3e66.4 0.110 273.6
OSP_ md_
Age_ (years) 641 53.7 (5.9) 44.6e66.7 178 55.9 (5.7) 45.3e66.2 0.001 217.3
BMI_ (kg/m2) 641 24.9 (3.9) 16.8e47.3 178 26.8 (4.4) 18.4e43.3 0.001 217.3
COMP_ (mg/ml) 612 1598.8 (338.7) 745e3,101 172 1702.0 (375.8) 943e3,436 0.001 219.4
Aggrecan_ (mg/ml) 612 2942.5 (787.6) 1,235e6,230 172 2834.3 (768.1) 1,471e5,740 0.055 219.4
cIAP_ (ng/mmol) 612 1640.8 (1011.6) 100e6,846 172 1757.8 (1035.0) 100e5,332 0.155 219.4
NTx_ (nmol/mmol) 610 17.0 (4.7) 8.0e58.4 172 17.5 (4.8) 7.3e38.2 0.100 219.9
OSP_lt_
Age_ (years) 684 53.8 (5.8) 44.6e66.3 128 55.6 (6.0) 45.3e66.7 0.002 157.6
BMI (kg/m2) 684 24.9 (3.7) 16.8e47.3 128 27.1 (4.7) 18.6e44.5 0.001 157.6
COMP (mg/ml) 654 1595.9 (334.3) 745e3,101 126 1,677.0 (366.4) 984e3,436 0.027 161.5
Aggrecan (mg/ml) 654 2931.6 (792.8) 1,235e6,230 126 2806.0 (783.1) 1,628e5,740 0.043 161.5
cIAP (ng/mmol) 654 1671.2 (1006.6) 100e6,846 126 1595.3 (978.3) 100e4,900 0.374 161.5
NTx (nmol/mmol) 653 17.0 (4.7) 8.0e58.4 126 16.6 (4.1) 7.3e35.7 0.668 161.7
JSN_md_
Age_ (years) 638 54.4 (6.0) 44.6e66.2 90 54.7 (6.0) 45.5e65.8 0.674 123.6
BMI_ (kg/m2) 638 25.4 (4.0) 16.8e47.2 90 26.3 (5.2) 17.6e44.5 0.268 123.6
COMP_ (mg/ml) 606 1620.8 (354.4) 725e3,436 88 1621.9 (317.5) 965e2,827 0.808 126.8
Aggrecan_ (mg/ml) 606 2947.6 (799.3) 1,235e6,240 88 2762.5 (776.1) 1,471e5,230 0.035 126.8
cIAP_ (ng/mmol) 606 1648.4 (993.2) 100e6,846 88 1646.9 (1029.1) 150e4,900 0.877 126.8
NTx_ (nmol/mmol) 604 17.0 (4.4) 7.3e38.2 88 16.8 (3.9) 10.4e32.8 0.846 127.1
JSN_lt_
Age_ (years) 792 54.4 (5.9) 44.6e66.3 34 55.6 (6.0) 45.3e64.8 0.229 41.2
BMI_ (kg/m2) 792 25.4 (4.2) 16.8e47.3 34 27.3 (5.1) 20.8e44.5 0.024 41.2
COMP_ (mg/ml) 755 1619.5 (349.5) 725e3,436 33 1722.7 (345.4) 918e2,764 0.028 41.9
Aggrecan_ (mg/ml) 755 2915.9 (793.9) 1,235e6,240 33 2908.6 (819.4) 1,709e4,912 0.843 41.9
cIAP_ (ng/mmol) 755 1664.5 (1005.1) 100e6,846 33 1607.2 (1093.0) 464e4,900 0.524 41.9
NTx_ (nmol/mmol) 753 17.0 (4.7) 7.3e58.4 33 16.4 (4.3) 10e29.2 0.486 42.0
Incidence/1,000 e means the risk of new cases development over 10 years, per 1,000 individuals in the study population.
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The main goal of this study was to examine the extent to which
four study biomarkers (COMP, aggrecan, NTx, cIAP) predict inci-
dence of the RKOA in general population In future, disease-
modifying therapy selection in OA will be based on biomarkers
and will slow the progression of KOA. To identify biomarkers we
used the Chingford cohort e Caucasians females from northeast
London, assessed for RKOA at baseline and 10 years later. After
excluding women affected at baseline, we compared potential
predictors in those who developed RKOA after 10-year follow-up
(case) with women who remained unaffected (control). We
examined prediction testing speciﬁcally in each RKOA phenotype,
i.e., K/L, JSN and OSP grades. Our main ﬁndings were: (1) Higher
serum concentrations of COMP at baseline predicted increased risk
of K/L  2 appearance after 10 years; (2) Serum concentrations of
aggrecan at baseline were found inversely associated with JSN in
medial compartment after 10 years of follow-up. That is, low levels
of aggrecan were associated with increased risk of RKOA incidence,
caused probably by loss of cartilage. (3) Age and BMI as expected
were signiﬁcant predictors of several RKOA phenotypes, specif-
ically, K/L, OSP in both medial and lateral compartments, and BMIwas a reliable predictor of JSN_lt (Table II). Thus our study conﬁrms
the association of age and BMI with RKOA. However, the most
remarkable ﬁndings of the present study were an ability of aggre-
can and COMP circulating levels to predict incidence of some RKOA
phenotypes, 10 years after the assays were taken (Fig. 1 & Table II).
Aggrecan is one of the ﬁrst matrix components to undergo
measurable loss in arthritic disease. Degradation of articular carti-
lage is a central feature in KOA involving the catabolism of the two
major constituents of cartilage matrix, type II collagen (CII) and
aggrecan13,32. Proteolytic destruction of type II collagen and
aggrecan by MMPs (matrix metalloproteases) and by ADAM-TS (a
disintegrin and metalloproteinase with thrombospondin motifs)36
leads to the cartilage loss observes in KOA. Previous studies
where aggrecan concentration was taken from synovial ﬂuid found
a dose response association between aggrecan concentration and
OA grading12,21,22. Other studies, however, found a strong19,20 or
weak37 negative association between synovial ﬂuid aggrecan con-
centration and loss of joint space. However, no data are so far
available on the levels of aggrecan serum concentration as prog-
nostic biomarker of RKOA. There may be several reasons for these
discrepancies. The ﬁrst is the origin of the aggrecan fragments
(synovial or serum or urine), the second is the stage of OA (early or
Table II
Parameter estimates in binary logistic regression analysis testing association be-
tween the incidence of RKOA-related phenotypes during 10 years and circulating
biomarkers, measured at entrance examination. Comments. Only participants that
at baseline and after 10 years follow-up were with “no affected” radiographic im-
aging (control) vs unaffected at baseline but affected after 10 years (case) were
examined in this analysis.
Predictors B(SE) RR 95% CI P
K/L_(742)
Constant 8.64 (3.600) 0.016
Age_ (years) 0.053 (0.015) 1.055 1.024e1.086 0.001
BMI_ (kg/m2) 0.094 (0.022) 1.099 1.052e1.147 0.001
COMP_ (mg/ml) 1.055 (0.447) 2.871 1.195e6.894 0.018
Aggrecan 0.682 (0.353) 0.505 0.253e1.10 0.053
OSP_ md_(819)
Constant 12.34 (3.154) 0.001
Age_ (years) 0.057 (0.015) 1.059 1.027e1.091 0.001
BMI_ (kg/m2) 0.099 (0.021) 1.104 1.058e1.151 0.001
COMP_ (mg/ml) 0.001 (0.001) 1.000 1.000e1.001 0.090
OSP_lt_(812)
Constant 8.49 (4.236) 0.045
Age_ (years) 0.045 (0.018) 1.046 1.011e1.083 0.010
BMI_ (kg/m2) 0.122 (0.024) 1.130 1.078e1.184 0.001
COMP_ (mg/ml) 0.001 (0.001) 1.000 1.000e1.001 0.139
Aggrecan 0.001 (0.001) 1.000 1.000e1.000 0.195
JSN_md_(694)
Constant 5.81 (3.475) 0.095
Aggrecan 0.977 (0.440) 0.376 0.159e0.891 0.026
JSN_lt_ (826)
Constant 13.53 (6.307) 0.032
BMI_ (kg/m2) 0.083 (0.036) 1.086 1.012e1.166 0.022
COMP_ (mg/ml) 0.001 (0.001) 1.001 1.000e1.002 0.214
B(SE) and RR e represent regression coefﬁcient estimates, their corresponding
standard errors and relative risk, for each signiﬁcant covariate and/or predictor
variable.
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Fig. 1. Risk probability for RKOA (K/L grade 2) in Chingford study at age 50 years (A),
60 years (B) and 70 years (C) as a function of BMI and circulating levels of COMP. Values
are the mixed-effects logistic model parameter estimates (see Table II) for three mean
categories of BMI (25 kg/m2, 35 kg/m2, 45 kg/m2) and for tertiles of COMP (1 ¼ 933 pg/
ml, 2 ¼ 1,551 pg/ml, 3 ¼ 2649.5 pg/ml). All COMP data were logarithm-transformed.
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amount of inﬂammation in the joint and the ﬁfth is the disease’ rate
of progression6,20,36,38.
COMP is an important non-collagenous protein synthesized by
chondrocytes and is abundant in OA cartilage9. Its synthesis is
increased when chondrocytes and synovial cells are activated by
pro-inﬂammatory cytokines39. Previous studies found that
increased amounts of COMP fragments were released into the joint
ﬂuid and serum in KOA patients andwere associatedwith diagnosis
of OA and prognosis of cartilage loss24,40,41. Also, serum levels of
COMP are heritable42 showing that they are under genetic control.
Important, the COMP prediction of cartilage loss remained statis-
tically signiﬁcant even after adjustment for age, gender and
BMI23,25,43. Although, the data are not consistent with respect to the
predicted phenotype, Ling et al.44 found in Baltimore longitudinal
study that COMP is a predictive biomarker of RKOA as is manifested
by K/L grading, 7e10 years later after assay. Golightly and col-
leagues45 reported that COMPwas highly predictive of incident OSP
and JSN, but did not ﬁnd statistically signiﬁcant associationwith K/L
grading. Our ﬁndings suggest that COMP may be a useful indicator
for identifying new RKOA and it might be associated with a com-
bination of OSP and joint space as both are measured by K/L
grading, and not to each of them separately. Finally, as seen in Fig. 1,
the strength of association of COMP with risk of RKOA reﬂects also
its interplay with age and BMI of the individual.
One of the potential limitations of this study is that biological
markers were derived from blood serum or urine and not from
synovial ﬂuid of knee joint; the information on knee joint status in
particular could only be estimated, however these will be the
preferred methods in routine clinical practice. The second limita-
tion is that the radiographs were taken with patients’ knees fully
extended in weight bearing position, a position that is lessappropriate to evaluate JSN, and therefore some cases may have
been missed, leading to an underestimate of the association be-
tween markers and JSN. However, the strength of this study in fact
that it used a relatively large sample at entrance and 10 years later.
Thus the present longitudinal study is probably one of the most
reliable projects in this ﬁeld.
In conclusion, KOA is a disease characterized by dynamic
changes in tissue macromolecule turnover, which is reﬂected by
measurable biomarkers’ serum concentration, COMP and aggrecan,
which can predict to some extent who will (and will not) go on to
develop RKOA. It will be important to keep on exploring for
biochemical markers and understanding the chemical relations
during the joint arthritic changes will help us to accelerate toward
therapeutic development that will slow the progress of the disease.
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Sample sizes used in present study at baseline and 10 years after bas
the “affected” individuals observed at baseline examination, and by ea
RKOA-phenotype Baseline
Total Affected Not aff
K/L 909 134 775
K/L þ Comp 865 123 742
K/L þ Aggrecan 865 123 742
K/L þ cIAP 865 123 742
K/L þ NTx 863 122 741
OSP_md 909 88 821
OSP_md þ Comp 865 81 784
OSP_md þ Aggrecan 865 81 784
OSP_md þ cIAP 865 81 784
OSP_md þ NTx 863 81 782
OSP_lt 909 94 815
OSP_lt þ Comp 865 84 781
OSP_lt þ Aggrecan 865 84 781
OSP_lt þ cIAP 865 84 781
OSP_lt þ NTx 863 83 780
JSN_md 909 180 729
JSN_md þ Comp 865 171 694
JSN_md þ Aggrecan 865 171 694
JSN_md þ cIAP 865 171 694
JSN_md þ NTx 863 171 692
JSN_lt 909 82 827
JSN_lt þ Comp 865 78 787
JSN_lt þ Aggrecan 865 78 787
JSN_lt þ cIAP 865 78 787
JSN_lt þ NTx 863 83 780
Prediction study (after exclusion of the effected individuals from baseline sample)
K/L 773 0 773
K/L þ Comp 742 0 742
K/L þ Aggrecan 742 0 742
K/L þ cIAP 742 0 742
K/L þ NTx 741 0 741
OSP_md 819 0 819
OSP_md þ Comp 784 0 784
OSP_md þ Aggrecan 784 0 784
OSP_md þ cIAP 784 0 784
OSP_md þ NTx 782 0 782
OSP_lt 812 0 812
OSP_lt þ Comp 780 0 780
OSP_lt þ Aggrecan 780 0 780
OSP_lt þ cIAP 780 0 780
OSP_lt þ NTx 779 0 779
JSN_md 728 0 728
JSN_md þ Comp 694 0 694
JSN_md þ Aggrecan 694 0 694
JSN_md þ cIAP 694 0 694
JSN_md þ NTx 692 0 692
JSN_lt 826 0 826
JSN_lt þ Comp 788 0 788
JSN_lt þ Aggrecan 788 0 788
JSN_lt þ cIAP 788 0 788
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After 10 years
ected Total Affected Not affected (N)
907 340 567
865 324 541
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907 260 647
865 247 618
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863 247 616
906 220 686
864 208 656
864 208 656
864 208 656
862 207 655
907 209 698
865 201 664
865 201 664
865 201 664
863 201 662
907 69 838
865 67 798
865 67 798
865 67 798
863 67 796
773 208 565
742 203 539
742 203 539
742 203 539
741 203 538
819 178 641
784 172 612
784 172 612
784 172 612
782 172 610
812 128 684
780 126 654
780 126 654
780 126 654
779 126 653
728 90 638
694 88 606
694 88 606
694 88 606
692 88 604
826 34 792
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788 33 755
786 33 753
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